Zachary Z. Brener
Research Subjects
Research Interests
Zachary Z. Brener has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Michael Bergman
Department of Medicine, Hasharon Hospital , Rabin Medical Center, Tel-Aviv University , Tel Aviv , Israel
6 shared publicationsJames F. Winchester
5 shared publications- Michael Bergman
Department of Medicine C, Rabin Medical Center-Hasharon Hospital, Petah-Tiqva, Israel; Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Israel
4 shared publications - Peter Kotanko
Renal Research Institute, New York, NY 10065, USA
2 shared publications Stephan Thijssen
2 shared publicationsAdam Brenner
ICU, Mount Sinai Medical Center, Brooklyn, NY, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 9 (1) , 67-71
Effectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury
The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. Recent findings indicate an increased risk for kidney involvement, including progressive acute kidney injury (AKI) during COVID-19 infection, specifically in critically ill patients, and associated with high mortality rates. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive with a frequent need for renal replacement therapy (RRT). Convalescent plasma (CP) has been approved as an emergency investigational drug with clinical benefits in observational studies. We described a first case of a patient with severe COVID-19 and AKI who had remarkable improvement in his respiratory status and in kidney function following CP therapy. Our findings demonstrate important therapeutic implications of effective multimodality therapy including CP when treating patients with COVID-19 and AKI.
- 1 January 2021
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 9 (1) , 67-71
Open AccessEffectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury
The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. Recent findings indicate an increased risk for kidney involvement, including progressive acute kidney injury (AKI) during COVID-19 infection, specifically in critically ill patients, and associated with high mortality rates. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive with a frequent need for renal replacement therapy (RRT). Convalescent plasma (CP) has been approved as an emergency investigational drug with clinical benefits in observational studies. We described a first case of a patient with severe COVID-19 and AKI who had remarkable improvement in his respiratory status and in kidney function following CP therapy. Our findings demonstrate important therapeutic implications of effective multimodality therapy including CP when treating patients with COVID-19 and AKI.
- 13 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1735-1737
Bruton’s tyrosine kinase inhibitors and the kidney: Focus on ibrutinib
Introduction: Tumor lysis syndrome is an oncologic emergency resulting from rapid and massive tumor cell death that may lead to serious clinical complications including acute kidney injury and cardiac arrest. Tumor lysis syndrome most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas and acute lymphoblastic leukemia. Case report: We present a first case of patient with chemotherapy-resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who developed tumor lysis syndrome upon treatment with ibrutinib (Imbruvica), a novel tyrosine kinase inhibitor. Management and outcome: The patient showed dramatic improvement in kidney function, uric acid and phosphorus after discontinuation of ibrutinib and a short course of rasburicase (recombinant urate oxidase), and two haemodialysis treatments. Discussion: Clinicians should be aware of this serious side effect and closely monitor kidney function in patients treated with this oral kinase inhibitor.
- 13 February 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1735-1737
Bruton’s tyrosine kinase inhibitors and the kidney: Focus on ibrutinib
Introduction: Tumor lysis syndrome is an oncologic emergency resulting from rapid and massive tumor cell death that may lead to serious clinical complications including acute kidney injury and cardiac arrest. Tumor lysis syndrome most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas and acute lymphoblastic leukemia. Case report: We present a first case of patient with chemotherapy-resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who developed tumor lysis syndrome upon treatment with ibrutinib (Imbruvica), a novel tyrosine kinase inhibitor. Management and outcome: The patient showed dramatic improvement in kidney function, uric acid and phosphorus after discontinuation of ibrutinib and a short course of rasburicase (recombinant urate oxidase), and two haemodialysis treatments. Discussion: Clinicians should be aware of this serious side effect and closely monitor kidney function in patients treated with this oral kinase inhibitor.
- Open Access
- 23 June 2014
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 7 (4) , 399-401
Necrotizing pancreatitis due to hypercalcemia in a hemodialysis patient with pica
Pica refers to the persistent, compulsive craving for and ingestion of nonfood items and certain food items. Pica is quite common among dialysis patients. The nutrient composition of some of the substances ingested may contribute to severe metabolic and mineral disturbances and other serious medical complications. We report the first case of a hemodialysis patient with chalk pica associated hypercalcemia who developed acute necrotizing pancreatitis. Hydration, nutritional support and hemodialysis treatments with low-calcium bath led to clinical improvement and correction of his calcium. This case illustrates the dangers of pica in dialysis patients and describes modalities of treatment and detection of this high risk behavior.
- 23 June 2014
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 7 (4) , 399-401
Open AccessNecrotizing pancreatitis due to hypercalcemia in a hemodialysis patient with pica
Pica refers to the persistent, compulsive craving for and ingestion of nonfood items and certain food items. Pica is quite common among dialysis patients. The nutrient composition of some of the substances ingested may contribute to severe metabolic and mineral disturbances and other serious medical complications. We report the first case of a hemodialysis patient with chalk pica associated hypercalcemia who developed acute necrotizing pancreatitis. Hydration, nutritional support and hemodialysis treatments with low-calcium bath led to clinical improvement and correction of his calcium. This case illustrates the dangers of pica in dialysis patients and describes modalities of treatment and detection of this high risk behavior.
- 30 June 2011
- Published by Springer Nature in Clinical & Translational Metabolism
- Vol. 9 (3-4) , 198-206
Calcium Nephrolithiasis
- 30 June 2011
- Published by Springer Nature in Clinical & Translational Metabolism
- Vol. 9 (3-4) , 198-206
Calcium Nephrolithiasis
- 1 February 2011
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 104 (2) , 133-139
Nephrolithiasis: Evaluation and Management
Nephrolithiasis is a major cause of morbidity involving the urinary tract. The prevalence of this disease in the United States has increased from 3.8% in the 1970s to 5.2% in the 1990s. There were nearly two million physician-office visits for nephrolithiasis in the year 2000, with estimated annual costs totaling $2 billion. New information has become available on the clinical presentation,...
- 1 February 2011
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 104 (2) , 133-139
Nephrolithiasis: Evaluation and Management
Nephrolithiasis is a major cause of morbidity involving the urinary tract. The prevalence of this disease in the United States has increased from 3.8% in the 1970s to 5.2% in the 1990s. There were nearly two million physician-office visits for nephrolithiasis in the year 2000, with estimated annual costs totaling $2 billion. New information has become available on the clinical presentation,...
- 14 January 2011
- Published by S. Karger AG in Blood Purification
- Vol. 31 (4) , 243-251
The Impact of Residual Renal Function on Hospitalization and Mortality in Incident Hemodialysis Patients
Background/Aims: Few data are available on the impact of residual renal function (RRF) on mortality and hospitalization in hemodialysis (HD) patients. The objective of our study was to compare clinical outcomes for HD patients with and without RRF. Methods: In a cohort of 118 incident HD patients with RRF (n = 51) and without RRF (n = 67) who started dialysis in a single center, we recorded demographics, laboratory data, medication, hospitalizations and mortality. Results: Patients without RRF were older (p = 0.007), had lower baseline serum albumin levels (p = 0.002) and spent 18.6 more days in hospital per year than those with RRF (p = 0.055). Mean survival time was significantly lower in patients without RRF (p = 0.027). In a Cox proportional hazards model, only RRF remained as a significant independent predictor. Conclusions: RRF is associated with significantly reduced mortality and hospital days, but does not decrease the hospitalization rate and time to first hospitalization.
- 14 January 2011
- Published by S. Karger AG in Blood Purification
- Vol. 31 (4) , 243-251
The Impact of Residual Renal Function on Hospitalization and Mortality in Incident Hemodialysis Patients
Background/Aims: Few data are available on the impact of residual renal function (RRF) on mortality and hospitalization in hemodialysis (HD) patients. The objective of our study was to compare clinical outcomes for HD patients with and without RRF. Methods: In a cohort of 118 incident HD patients with RRF (n = 51) and without RRF (n = 67) who started dialysis in a single center, we recorded demographics, laboratory data, medication, hospitalizations and mortality. Results: Patients without RRF were older (p = 0.007), had lower baseline serum albumin levels (p = 0.002) and spent 18.6 more days in hospital per year than those with RRF (p = 0.055). Mean survival time was significantly lower in patients without RRF (p = 0.027). In a Cox proportional hazards model, only RRF remained as a significant independent predictor. Conclusions: RRF is associated with significantly reduced mortality and hospital days, but does not decrease the hospitalization rate and time to first hospitalization.
- 1 January 2011
- Published by E-MED LTD in Grand Rounds
- Vol. 11 (1) , 53-55
Hypokalaemia in a woman with eating disorder
Hypokalaemia in a woman with eating disorder - Grand Rounds Hypokalaemia in a woman with eating disorder - Chronic hypokalaemia often remains a diagnostic challenge, especially in young women without hypertension. A concealed diuretic abuse should be suspected, especially in young women with eating disorders. This case describes a woman with chronic hypokalaemia in whom a thorough medical history and proper laboratory tests were essential to early and accurate diagnosis.
- 1 January 2011
- Published by E-MED LTD in Grand Rounds
- Vol. 11 (1) , 53-55
Hypokalaemia in a woman with eating disorder
Hypokalaemia in a woman with eating disorder - Grand Rounds Hypokalaemia in a woman with eating disorder - Chronic hypokalaemia often remains a diagnostic challenge, especially in young women without hypertension. A concealed diuretic abuse should be suspected, especially in young women with eating disorders. This case describes a woman with chronic hypokalaemia in whom a thorough medical history and proper laboratory tests were essential to early and accurate diagnosis.
- Open Access
- 10 August 2010
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 4 (1) , 261
Acute liver failure following hemodialysis arteriovenous graft placement: a case report
Severe high-output cardiac failure is a serious complication of high-flow vascular access requiring immediate intervention. Ischemic hepatitis is defined as a massive increase in serum transaminase levels due to an imbalance between hepatic oxygen supply and demand in the absence of other acute causes of liver damage. It is typically preceded by hypotension, hypoxemia, or both, and occurs mostly in elderly patients with right-sided congestive heart failure.
- 10 August 2010
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 4 (1) , 261
Open AccessAcute liver failure following hemodialysis arteriovenous graft placement: a case report
Severe high-output cardiac failure is a serious complication of high-flow vascular access requiring immediate intervention. Ischemic hepatitis is defined as a massive increase in serum transaminase levels due to an imbalance between hepatic oxygen supply and demand in the absence of other acute causes of liver damage. It is typically preceded by hypotension, hypoxemia, or both, and occurs mostly in elderly patients with right-sided congestive heart failure.
- 1 May 2010
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 339 (5) , 453-456
Clinical Benefit of Preserving Residual Renal Function in Dialysis Patients: An Update for Clinicians
- 1 May 2010
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 339 (5) , 453-456
Clinical Benefit of Preserving Residual Renal Function in Dialysis Patients: An Update for Clinicians
- 1 July 2009
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 338 (1) , 78
Rhabdomyolysis Following Clarithromycin Monotherapy
- 1 July 2009
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 338 (1) , 78
Rhabdomyolysis Following Clarithromycin Monotherapy